Insulin-dependent diabetes mellitus (IDDM) is the consequence of an autoimmune destruction of the pancreatic beta cells. Both humoral and cell-mediated immune responses to beta-cell antigens have been observed [1] . Islet cell antibodies (ICA), now considered a heterogeneous series of antibodies against several beta-cell molecules, were first detected in 1974 [2] , and insulin autoantibodies (IAA) were subsequently found in patients with newly diagnosed IDDM before exogenous insulin therapy [3] . Antibodies immunoprecipitating islet 64 kDa proteins were also detected [4] and their target later identified as the 65 kDa isoform of glutamic acid decarboxylase (GAD) [5] . More recently, antibodies against a protein tyrosine phosphatase-like transmembrane protein called the 40 000 M r protein [6] , ICA512 [7] or were identified in patients with IDDM. Both ICA512 and IA-2 were characterized biochemically, and it turned out that they were identical in DNA sequence [9] . The 40 kDa protein is a rat homologue of the intracellular portion of Diabetologia (1998) Summary To study the relationship of IA-2 antibodies (IA-2A) to other autoantibodies and genetic risk markers in insulin-dependent diabetes mellitus (IDDM), 758 children and adolescents younger than 15 years of age (mean age 8.4 years) with newly diagnosed diabetes were analysed for IA-2A, GAD antibodies (GADA) and insulin autoantibodies (IAA) with radiobinding assays, for islet cell antibodies (ICA) with immunofluorescence and for HLA DR alleles by serology. IA-2A were detected in 85.9 % of cases with no association with gender or age. An overwhelming majority of the patients (71.3 %) tested positive for three or more antibodies, and 90.7 % for at least two. Fifty-four subjects (7.1 %) had one antibody detectable, whereas only 2. 
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ICA512/IA-2 [10] . ICA512/IA-2 is expressed in neuroendocrine cells, including beta, alpha and delta cells in the pancreatic islets, pituitary cells and cells in the adrenal medulla [9, 11] . Subcellularly, it is restricted to the membranes of neurosecretory granules [9, 11] . It has been reported that 50±70 % of patients with newly diagnosed diabetes have autoantibodies to ICA512/IA-2 [6, 9, 12] . We report here observations on antibodies to the intracellular portion of the IA-2 molecule (IA-2A) in relation to GAD antibodies (GADA), ICA, IAA and HLA DR alleles in a large population-based series of children with newly diagnosed IDDM.
Subjects and methods
Subjects. The population comprised 758 children under the age of 15 years (mean 8.4, range 0.78±14.97 years) with newly diagnosed IDDM, including 418 boys, a male excess (55.1 %). The population included 93.5 % of all IDDM patients in this age group diagnosed in Finland during the period from 1 September 1986 to 30 April 1989, and represents the index cases in the nationwide ªChildhood Diabetes in Finlandº (DiMe) study, which has been described in detail elsewhere [13] . The study protocol was approved by the ethical committees of all participating hospitals. Blood samples were taken at the time of diagnosis of diabetes and the sera were stored at 20 C until assayed. Blood samples were in addition collected from 374 non-diabetic Finnish subjects aged 0±19 years to define the cut-off limits for positivity for IA-2A, GADA and IAA (defined as the 99th percentiles). The control population represents normal Finnish children and adolescents. The blood samples were taken after informed consent from the subjects and/ or the parents at child welfare clinics, schools or at prearranged visits to the outpatient clinic at the Department of Pediatrics, University of Oulu. The 105 control subjects used for assessing the 99th percentile of IAA were derived at random from the total group of 374.
IA-2 antibody assay. IA-2A were analysed with a radiobinding assay modified from that described by Bonifacio et al. [14] . The recombinant plasmid pSP64poly(A) encoding the intracellular portion of the full length IA-2 protein, including amino acids 605±979 (provided by E. Bonifacio, Milan, Italy) was transformed in Escherichia coli JM109 cells and then purified by standard techniques [15] . The IA-2 protein was produced with in vitro transcription and translation of the purified plasmid by the TNT Coupled Reticulocyte Lysate System (Promega, Madison, Wis., USA) in the presence of S-methionine was removed by gel chromatography on a NAP-5 column (Pharmacia, Uppsala, Sweden). Serum samples of 2 ml were incubated at +4 C overnight in 96 deep well plates with 10 000 cpm of labelled IA-2 protein diluted in 50 ml of 50 mmol/l Tris and 150 mmol/l NaCl (pH 7.4) containing 0.1 % Tween 20 (TBST). On the next day 5 ml Protein A Sepharose CL-4B (Pharmacia) in a total volume of 50 ml TBSTwas added to isolate the immune complexes. After incubation for at least 1 h on a shaker at +4 C, the samples were transferred to a 96-well opaque filtration plate with a 0.45 mm Durapore filter at the bottom of each well (Millipore, Bedford, Mass., USA). The samples were washed 10 times with approximately 150 ml TBST using a vacuum device (Millipore). After a short drying period, 10 ml of scintillation fluid (OptiPhase Supermix; Wallac, Turku, Finland) was added and the activity of the samples was measured in a liquid scintillation counter (1450 Microbeta Trilux; Wallac). All the samples were tested in duplicate. In addition, each plate contained a dilution series of a pool of two local positive sera diluted in a pool of two local negative sera. A standard curve was constructed on each plate using the cpm results of the dilution series (1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128; 1:512 and the pool of the two negative sera), the dilution being assigned arbitrary values of 100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78, 0.39 and 0.1 relative units (RU), respectively. The standard curve was a log 10 /log 10 curve created separately for each plate by a software program (MultiCalc; Wallac), which was also used to handle the results and to combine the patient codes and relative units. The limit for positivity (0.43 RU) was set at the 99th percentile for 374 non-diabetic Finnish children and adolescents. All samples with IA-2A levels exceeding 100 RU were diluted and reanalysed until the result could be read from the standard curve and the final IA-2A level was obtained by multiplying the relative units by the dilution factor. The receiver operating characteristic (ROC) curve based on the IA-2A levels in the 758 children with newly diagnosed diabetes and 374 unaffected Finnish children and adolescents is shown in Figure 1 . The interassay coefficient of variation was 12 % at an IA-2A level of 0.63 RU, 10 % at a level of 21.3 RU and 8 % at a level of 82.6 RU. The disease sensitivity of our assay was 62 % and the specificity 97 % based on 140 samples included in the 1995 Multiple Autoantibody Workshop.
GAD65 antibody assay. GADA were measured with a radioligand assay as previously described [16, 17] . The cut-off limit for antibody positivity was set at the 99th percentile for 372 non-diabetic children and adolescents, i. e. 6.6 RU. The interassay coefficient of variation was 18 % at a GADA level of 14.6 RU and 12 % at GADA levels exceeding 100 RU. The Islet cell antibody assay. ICA were measured by a standard immunofluorescence method, using sections of frozen human group 0 pancreas [2] . End-point dilution titres were examined for the positive samples, and the results were expressed in Juvenile Diabetes Foundation (JDF) units relative to an international reference standard [18] . The detection limit was 2.5 JDF units. Our laboratory has participated in the international workshops on standardization of the ICA assay, in which its sensitivity was 100 %, specificity 98 %, validity 98 %, and consistency 98 % in the most recent round [19] .
Insulin autoantibody assay. Serum IAA levels were determined with a radiobinding assay modified from that described by Palmer et al. [3] . Endogenous insulin was removed with acid-charcoal before the assay, and free and bound insulin were separated after incubation with mono-125 I(Tyr A14 )-human insulin (Novo Research Institute, Bagsvaerd, Denmark) for 20 h in the presence or absence of an excess of unlabelled insulin. IAA levels were expressed in nU/ml, where 1 nU/ml corresponds to a specific binding of 0.01 % of the total counts. The interassay coefficient of variation was less than 8 %. A subject was considered to be positive for IAA, when specific binding exceeded 54 nU/ml (99th percentile for 105 non-diabetic subjects). The disease sensitivity of this assay was 26 % and the specificity 97 % based on 140 samples included in the Multiple Autoantibody Workshop.
HLA typing. HLA alleles were typed using conventional HLA serology as described previously [20] . All HLA DR specificities recognized by the Nomenclature Committee of the WHO in 1984 were included in the test panel [21] . HLA typing data were available for 730 of the patients.
Statistical analysis. The data were evaluated statistically using cross-tabulation and chi-square statistics, the MannWhitney U test, Kruskall-Wallis one-way ANOVA and Spearman's non-parametric correlation analysis (r s ) (SPSS for Windows; SPSS Inc., Chicago, Ill., USA). The Bonferroni 
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Frequencies and levels of IA-2A. IA-2A were detected in 651 subjects (85.9 %; CI 83.4±88.4 %), the median level in whom was 64.5 RU, with a range of 0.45 to 4500 RU. The boys and girls had similar frequencies and levels of IA-2A. There were no significant differences in the IA-2A frequencies when the subjects were classified into three age groups (0±4.9, 5±9.9 and 10±14.9 years) ( Table 1 ), but patients aged 5±9.9 years had higher IA-2A levels than the youngest children (63.8 RU vs. 17.4 RU, p < 0.01). Among those with IA-2A, about one tenth tested negative for ICA, one fifth for GADA and more than 40 % for IAA. These proportions varied, however, according to age (Table 1) .
Combinations and correlations between autoantibodies. The frequencies of various antibody combinations are given in Table 1 for both the whole study population and separately for the three age groups. An overwhelming majority of the patients (71.4 %, CI 68.2±74.6 %) tested positive for at least three disease-associated autoantibodies, while 90.8 % (CI 88.5±92.7 %) were positive for two or more antibodies. Less than one tenth of the cases (54; 7.1 %, CI 5.4±9.2 %) had one antibody detectable, and only 2.1 % (CI 1.2±3.4 %) tested negative for all four. The boys and girls had similar frequencies of multiple (at (Fig. 2) . Both ICA and IA-2A and/or GADA were detected in 625 patients (82.5 %, CI 79.7±85.2 %), while 99 of the remaining cases (13.1 % of all patients, CI 10.7±15.5 %) were identified by IA-2A and/or GADA and not by ICA, as opposed to 13 (1.7 % of all cases, CI 0.9±2.9 %) detected by ICA but not by IA-2A and/or GADA. There was a relatively close correlation (r s = 0.40, p < 0.001) between IA-2A and ICA levels after the exclusion of double negative subjects, while a weak inverse correlation was seen between IA-2A and GADA levels (r s = 0.09, p < 0.05). Levels of IA-2A correlated weakly with those of IAA (r s = 0.08, p < 0.05).
IA-2A and HLA risk markers. The prevalence of IA-2A was higher in cases carrying the HLA DR4/non-DR3 phenotype and lower in those with the HLA DR3/non-DR4 combination than in the other HLA DR groups (Table 2) , and the IA-2A levels followed the same pattern (Fig. 3) . The few patients with the DR2 allele (n = 24, 3.2 % of all cases) had IA-2A as often as the other subjects (83.3 vs 85.7 %, p = 0.98), and there was no significant difference in the IA-2A levels between those carrying the DR2 allele and the others (3.2 vs 44.2 RU; p = 0.23). The frequencies of ICA and IAA were decreased in the subjects with the HLA DR3/non-DR4 combination ( Table 2) . Multiple antibodies were less frequent in patients with HLA DR3/non-DR4 than in the patients with HLA DR3/DR4 or HLA DR4/non-DR3 (Table 2 , p < 0.001 for both comparisons).
Discussion
In the present study we found antibodies to IA-2 in a definite majority of children and adolescents with newly diagnosed IDDM (85.9 %), including 171 cases (22.6 % of all patients) with undetectable GADA. The prevalence of IA-2A observed in this Finnish cohort is high as compared with other reports. Both here and in a previous survey [22] , IA-2A were found to be more prevalent in patients with HLA DR4, the frequency of which is particularly high in Finnish patients with IDDM [23] . Moreover, antibodies to the 37/40 kDa protein have been reported previously to be associated with a young age at diagnosis [24, 25] . IA-2A were similarly found in a Belgian study to be more frequent in patients diagnosed before the age of 20 years than in those with clinical presentation at an older age [12] . Both the HLA characteristics and the age of the present cohort may therefore account for the high IA-2A prevalence.
The prevalence of IA-2A was similar in the girls and boys and in the children and adolescents. In this respect IA-2A differ from GADA, which are more frequent among girls and among patients over 10 years of age [17] , and also from ICA and IAA, which are associated with young age at the diagnosis of IDDM [26, 27] . Moreover, IA-2A were closely associated with HLA DR4, the strongest single allele predisposing to IDDM, while high GADA levels have been reported to be associated with HLA DR3 and DQB1*02 [17, 28] . These results indicate that IA-2A and GADA complement each other. Furthermore, GADA have been shown to be associated with thyroid microsomal and thyroglobulin antibodies both in patients with newly diagnosed IDDM and in their siblings [29] . This implies that GADA may be a sign of general autoimmunity in patients with IDDM, while IA-2A could be a more specific marker of beta-cell destruction. Our observation of a decreased frequency of ICA and IAA in patients carrying HLA DR3/ non-DR4 is consistent with most previous studies [28, 30, 31] .
Measurement of a combination of autoantibody markers has been suggested as a useful tool for determining the risk of IDDM [32] , and a number of screening strategies have been proposed [33] . The recent identification of IA-2 as an important IDDM associated autoantigen in addition to GAD has greatly facilitated the development of such strategies. In the present cohort 71.3 % of the patients had at least three disease-associated autoantibodies, whereas only 2.1 % (16 of 758) tested negative for all four, suggesting that almost all children with IDDM can be identified by screening for these four autoantibodies at diagnosis. The combination of IA-2A and/or GADA identified 95.5 % of the cases, supporting previous suggestions that a combined GADA/IA-2A test is likely to be useful for screening purposes. Since 90.8 % of all cases had at least two of the antibody markers tested, screening with IA-2A and GADA with subsequent testing of IAA and ICA in those found to be positive for IA-2A and/or GADA is likely to be an effective way of assessing the risk of IDDM. These antibodies are found prior to clinical disease onset and antibody measurements in pre-IDDM cases also show that a combination of GADA and IA-2A will be effective as a sensitive screen for future IDDM [32, 34] . The risk estimates yielded by the various antibody combinations and the importance of IAA and ICA in screening strategies will need to be evaluated by additional prospective studies on individuals progressing to clinical IDDM.
In summary, we have found that IA-2A are present in the majority of children with newly diagnosed IDDM, that they differ from GADA in their relationship to age, sex and HLA DR alleles, and that in combination with GADA they serve to identify over 95 % of newly diagnosed cases with diabetes. 
